GDTC
CytoMed Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · SG
$0.86
−5.49%Year over year
Reported trailing growth
- Revenue
- +43.0%
- EBITDA
- -9.7%
- EBIT
- -10.3%
- EPS
- +9.1%
- Free cash flow
- -29.8%
- Operating cash flow
- -44.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +366.7%
- EBITDA
- -65.0%
- EBIT
- -33.1%
- Net income
- -58.2%
- EPS
- -54.5%
- Free cash flow
- -7.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026